2000
DOI: 10.1078/0171-9335-00113
|View full text |Cite
|
Sign up to set email alerts
|

Vascular endothelial growth factor (VEGF) stimulates monocyte migration through endothelial monolayers via increased integrin expression

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
77
1
1

Year Published

2001
2001
2014
2014

Publication Types

Select...
5
4

Relationship

0
9

Authors

Journals

citations
Cited by 113 publications
(79 citation statements)
references
References 51 publications
0
77
1
1
Order By: Relevance
“…Although they may be a source of endothelial or other progenitor cells, they probably act principally through paracrine mechanisms. 1,2 BMDCs are currently being used to treat ischemic conditions in clinical trials. [3][4][5] However, given our rudimentary knowledge of how BMDCs act as agents of vascular growth and tissue repair, it is not surprising that results of clinical trials to date are mixed.…”
mentioning
confidence: 99%
“…Although they may be a source of endothelial or other progenitor cells, they probably act principally through paracrine mechanisms. 1,2 BMDCs are currently being used to treat ischemic conditions in clinical trials. [3][4][5] However, given our rudimentary knowledge of how BMDCs act as agents of vascular growth and tissue repair, it is not surprising that results of clinical trials to date are mixed.…”
mentioning
confidence: 99%
“…It is well known that neoangiogenesis is directly related to tumor hypoxia [16], leading to the secretion of VEGF fibroblasts with chemoatractism for macrophages and triggering the process of neoangiogenesis [17]. Moreover, hypoxia causes activation of fibroblasts by transforming them into myofibroblasts that secrete SDF1 and VEGF.…”
Section: Discussionmentioning
confidence: 99%
“…Aus diesem Grund ist es ein wichtiges therapeutisches Ziel, nach Möglichkeiten zu suchen, das Wachstum von Kollateralarterien zu stimulieren und damit diesen natürlichen Prozess zu opti mieren. Die klinische Anwendung von be kannten Wachstumsfaktoren wie "mono cyte chemoattractant protein1" (MCP1) [6], "vascular endothelial growth factor" (VEGF) [1,2,5], "basic fibroblast growth factor" (bFGF), "fibroblast growth factor 2" oder 4 (FGF2, FGF4) werden jedoch kontrovers diskutiert [10,13].…”
Section: Stimulierung Des Wachstums Peripherer Und Zerebraler Kollateunclassified